Evotec is driven by a singular purpose: to be at the forefront of advancing medicines that truly matter. Their expertise aligns perfectly with DIVA’s mission and strategic approach, as Evotec leads the way in drug discovery and development by combining cutting-edge science, innovative technologies, and strategic partnerships to accelerate the delivery of life-changing therapies.
We are very excited about Evotec joining DIVA in the collaborative pursuit of advancing digital biomarkers that offer the potential for enhanced translatability and better decision making within in vivo preclinical research, together with a positive impact on 3R related measures.
– Fraser Mcintosh, Executive Vice President, Head of Global In Vivo Pharmacology, Evotec
With Evotec joining DIVA, we’re eager to collaborate on pushing the boundaries of digital measures in preclinical in vivo research. We’re excited to share that Evotec will be leading our initiative to validate computer-vision-derived respiratory measures, which have the potential for value in multiple contexts of use, including respiratory disease models, assessment of seizures, safety and sleep, and general quality of life assessment. Together, we will advance digital measures for preclinical in vivo research through collaborative development, validation, adoption, and regulatory acceptance.
Welcome aboard, Evotec! We look forward to achieving new milestones together.